Research analysts at Bank of America began coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) in a research report issued on Monday, Briefing.com reports. The firm set a “buy” rating and a $29.00 price target on the biotechnology company’s stock. Bank of America‘s target price suggests a potential upside of 25.16% from […]
Swiss National Bank boosted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 3.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 224,000 shares of the biotechnology company’s stock after purchasing an additional 6,700 shares during […]
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) have been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month […]
Endurant Capital Management LP bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 28,187 shares of the biotechnology company’s stock, valued at approximately $1,143,000. Several other large investors have […]
Blair William & Co. IL reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 11.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 15,059 shares of the biotechnology company’s stock after selling 1,870 shares during the period. Blair William & Co. IL’s holdings in Arrowhead Pharmaceuticals were worth $611,000 […]